Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial

OBJECTIVE: This study aimed to assess the efficacy and safety of camrelizumab plus apatinib in patients with resectable hepatocellular carcinoma (HCC) as neoadjuvant therapy. METHODS: Initially, 20 patients with HCC were screened and 18 patients with resectable HCC were enrolled in this open-label,...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Yongxiang, Tang, Weiwei, Qian, Xiaofeng, Li, Xiangcheng, Cheng, Feng, Wang, Ke, Zhang, Feng, Zhang, Chuanyong, Li, Donghua, Song, Jinhua, Zhang, Hui, Zhao, Jie, Yao, Aihua, Wu, Xiaofeng, Wu, Chen, Ji, Guwei, Liu, Xisheng, Zhu, Feipeng, Qin, Lang, Xiao, Xuan, Deng, Zhenhua, Kong, Xiangyi, Li, Si, Yu, Yangyang, Xi, Wenjing, Deng, Wanglong, Qi, Chuang, Liu, Hanyuan, Pu, Liyong, Wang, Ping, Wang, Xuehao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981365/
https://www.ncbi.nlm.nih.gov/pubmed/35379737
http://dx.doi.org/10.1136/jitc-2022-004656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981365/
https://www.ncbi.nlm.nih.gov/pubmed/35379737
http://dx.doi.org/10.1136/jitc-2022-004656

Ejemplares similares